Plasma interleukin-22 level,variants in interleukin-22 gene polymorphism,and the severity of systemic lupus erythematosus among Egyptian pediatric and adolescents
Restricted accessResearch articleFirst published online 2021
Plasma interleukin-22 level,variants in interleukin-22 gene polymorphism,and the severity of systemic lupus erythematosus among Egyptian pediatric and adolescents
Our purpose was to investigate, for the first time, genotypes and alleles distribution of two single nucleotide polymorphisms (SNPs) of interleukin 22 (IL-22) (rs1012356 and rs2227485) in Egyptian pediatric and adolescents with systemic lupus erythematosus (SLE) and to evaluate the plasma IL-22 levels and their association with gene polymorphism and SLE risk and severity.
Methods
The TaqMan™ SNP genotyping assay on a real-time polymerase chain reaction (PCR) system was employed to evaluate the polymorphism’s genotypes. Plasma IL-22 levels were determined by using an enzyme-linked immunoabsorbent assay (ELISA).
Results
The frequencies and genotypes of rs2227485 and rs1012356 in IL-22 between SLE patients and controls also haplotypes formed by the same SNPs revealed no statistically significant difference (p > 0.05). Otherwise, logistic regression analysis revealed that patients carrying rs1012356 “TA + AA” genotype had increased risk for prediction of SLE activity (OR = 1.610, 95% CI = 1.339–2.760, p = 0.034) by lowering plasma IL-22 level.
Conclusions
Among Egyptian pediatric and adolescents, we confirm a combined model “TA + AA” in rs1012356 (A/T) of IL-22 in regression analysis, as an independent predictor for SLE activity by lowering IL-22 plasma levels. Despite neither SNP rs2227485 A/G in IL-22 gene nor haplotypes formed by the same two SNPs (rs2227485 A/G and rs1012356 A/T) were significantly associated with the clinical and/or laboratory manifestations of SLE.
WangRZengY-LQinH-M, et al.Association of interleukin 22 gene polymorphisms and serum IL-22 level with risk of systemic lupus erythematosus in a Chinese population. Clin Exp Immunol2018; 193(2): 143–151.
2.
MoultonVRTsokosGC. T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. J Clin Invest2015; 125: 2220–2227.
3.
RashwanEMoaazMMohannadN, et al.Interleukin-22 and tumor necrosis factor receptor associated factor 1 (traf1) in patients with rheumatoid arthritis and systemic lupus erythematosus: correlation with disease activity. Egypt J Rheumatol Clin Immunol2016; 4(1): 49–58.
4.
PellicoroARamachandranPIredaleJP, et al.Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol2014; 14: 181–194.
5.
TalaatRMAlrefaeySABassyouniIH, et al.Genetic polymorphisms of interleukin 6 and interleukin 10 in Egyptian patients with systemic lupus eythematosus. Lupus2015; 25(3): 255–264.
6.
ZhongWJiangYMaH, et al.Elevated levels of CCR6+ T helper 22 cells correlate with skin and renal impairment in systemic lupus erythematosus. Sci Rep2017; 7: 12962.
7.
WitteEWitteKWarszawskaK, et al.Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev2010; 21: 365–379.
8.
ZenewiczLAFlavellRA. Recent advances in IL-22 biology. Int Immunol2011; 23: 159–163.
9.
Mellor-PitaSCitoresMJCastejonR, et al.Decrease of regulatory T cells in patients with systemic lupus erythematosus. Ann Rheum Dis2006; 65: 553–554.
10.
FinnoCJAlemanMHigginsRJ, et al.Risk of false positive genetic associations in complex traits with underlying population structure: a case study. Vet J2014; 202: 543–549.
11.
MiossecPKornTKuchrooVK. Interleukin-17 and type 17 helper T cells. New Engl J Med2009; 361(9): 888–898.
12.
LinJYueLHChenWQ. Decreased plasma IL-22 levels and correlations with IL-22-producing T helper cells in patients with new-onset systemic lupus erythematosus. Scand J Immunol2014; 79: 131–136.
13.
PanH-FZhaoX-FYuanH, et al.Decreased serum IL-22 levels in patients with systemic lupus erythematosus. Clin Chim Acta2009; 401: 179–180.
14.
ChengFGuoZXuH, et al.Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis2009; 68: 604–606.
15.
AsadiPMohebbiSRHosseiniSM, et al.Evaluation of single nucleotide polymorphism in interleukin 22 (IL-22) gene and its association with chronic hepatitis B infection. Gastroenterol Hepatol bed bench2019; 12(4): 309–314.
16.
ChamblissJMAnsarMKelleyJP, et al.A Polymorphism in the catalase gene promoter confers protection against severe RSV bronchiolitis. Viruses2020; 12(1): 57.
17.
LinLXuWZhangG, et al.Association of interleukin-22 polymorphisms with the colon cancer: a case-control study. Immunol Lett2017; 188: 59–63.
18.
WegerWHoferAWolfP, et al.Common polymorphisms in the interleukin-22 gene are not associated with chronic plaque psoriasis. Exp Dermatol2009; 18: 796–798.
19.
PetriMOrbaiAMAlarcónGS, et al.Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64(8): 2677–2686.
20.
PetriMKimMYKalunianKC, et al.Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med2005; 353(24): 2550–2558.
21.
MillerSADykesDDPoleskyHF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res1988; 16: 1215.
22.
Abd El AzeemRAZedanMMSaadEA, et al.Single-nucleotide polymorphisms (SNPs) of antioxidant enzymes SOD2 and GSTP1 genes and SLE risk and severity in an Egyptian pediatric population. Clin Biochem2021; 88(C): 37–42.
23.
ZhangC-xWangH-yYinL, et al.Immunometabolism in the pathogenesis of systemic lupus erythematosus. J Trans Autoimmun2020; 3: 100046.
24.
BashalF. Hematological disorders in patients with systemic lupus erythematosus. Open Rheumatol J2013; 7: 87–95.
25.
QuCZhangJZhangX, et al.Value of combined detection of anti-nuclear antibody, anti-double-stranded DNA antibody and C3, C4 complements in the clinical diagnosis of systemic lupus erythematosus. Exp Ther Med2019; 17(2): 1390–1394.
26.
SongR-hLiQWangW, et al.Variants of interleukin-22 gene confer predisposition to autoimmune thyroid disease. Int J Endocrinol2017; 2017: 1–9.
27.
XuWPresnellSRParrish-NovakJ, et al.A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl Acad Sci U S A2001; 98: 9511–9516.
28.
WolkKHaugenHSXuW, et al.IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not. J Mol Med (Berl)2009; 87: 523–536.
29.
KimK-WKimH-RParkJ-Y, et al.Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum2012; 64: 1015–1023.
30.
LinJYueLHChenWQ. Decreased plasma IL-22 levels and correlations with IL-22-producing T helper cells in patients with new-onset systemic lupus erythematosus. Scand J Immunol2013; 79(2): 131–136.
31.
ZhaoLJiangZJiangY, et al.IL-22+CD4+ T-cells in patients with active systemic lupus erythematosus. Exp Biol Med2013; 238: 193–199.
32.
El-GazzarIIBahgatDMREl KhateebEM. IL22 in Egyptian SLE patients, could it reflect disease activity, skin or renal involvement or is it only an expensive ESR?. Egyptian Rheumatol2017; 39: 13–18.
33.
DuhenTGeigerRJarrossayD, et al.Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol2009; 10: 857–863.
34.
KagamiSRizzoHLLeeJJ, et al.Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol2010; 130: 1373–1383.
35.
YuBGuanMPengY, et al.Copy number variations of interleukin-17F, interleukin-21, and interleukin-22 are associated with systemic lupus erythematosus. Arthritis Rheum2011; 63: 3487–3492.
36.
DingGGZhangGLChenXC, et al.[A study on the relationship between single nucleotide polymorphisms of interleukin-22 and susceptibility to pulmonary tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi2012; 35: 596–600.
37.
LiaoFHsuYCKuoSH, et al.Genetic polymorphisms and tissue expression of interleukin-22 associated with risk and therapeutic response of gastric mucosa-associated lymphoid tissue lymphoma. Blood Cancer J2014; 4(10): eXX.
